Moderna and Merck have announced promising five-year data for a groundbreaking personalized cancer treatment that combines mRNA technology with immunotherapy to prevent melanoma from returning after surgery. According to Drugs.com, the results mark a significant milestone in the development of individualized neoantigen therapies, treatments designed specifically to target each patient’s unique cancer mutations.
What the Data Shows
In the Phase 2b KEYNOTE-942 trial, patients with high-risk stage III/IV melanoma who received intismeran autogene (mRNA-4157) alongside Merck’s Keytruda showed a 49% reduction in their risk of recurrence or death compared to those receiving Keytruda alone. This represents a sustained benefit over five years, far longer than typical treatment periods, suggesting the therapy may provide durable protection against cancer’s return.
The study included 157 melanoma patients who had undergone complete surgical removal of their tumors. Two-thirds received the combination therapy, while one-third received Keytruda by itself. Patients in the combination group received one dose of intismeran autogene every three weeks for nine doses, along with Keytruda for approximately one year.
How the Treatment Works
Intismeran autogene represents a novel approach to cancer prevention. The therapy begins with analysis of each patient’s tumor, identifying unique mutations—called neoantigens—that are specific to that individual’s cancer. Scientists then design a personalized mRNA vaccine encoding up to 34 of these mutations. When administered, the mRNA instructs cells to produce proteins resembling the cancer’s mutations, training the immune system to recognize and attack any cancer cells that may resurface.
By combining this personalized vaccine with Keytruda, an immune checkpoint inhibitor that removes the immune system’s brakes, the two-pronged approach appears to create a more powerful defense against recurrence.
Significance for Melanoma Patients
Melanoma remains the deadliest form of skin cancer. With over 100,000 new cases expected annually in the U.S. and more than 8,000 deaths, the disease poses a serious threat—particularly for patients with advanced stage III/IV tumors that have spread to lymph nodes or distant sites. Even after surgery successfully removes visible disease, recurrence rates remain concerningly high. These five-year results suggest intismeran autogene could meaningfully improve outcomes for this vulnerable population.
“For many patients with stage III/IV melanoma, there is a significant risk of recurrence following surgery,” noted Dr. Marjorie Green from Merck’s oncology division. “Demonstrating the longer-term potential to reduce recurrence risk is a meaningful milestone.”
Expanding the Pipeline
The successful five-year data from melanoma has energized efforts to expand this approach. Moderna and Merck are advancing multiple trials across different cancer types. A Phase 3 adjuvant melanoma study is fully enrolled, alongside Phase 3 trials in non-small cell lung cancer. Phase 2 studies are underway for renal cell carcinoma, bladder cancer, and metastatic melanoma.
The safety profile remained consistent throughout the five years, with no new safety concerns emerging.
Looking Ahead
These results represent validation of mRNA’s potential in cancer prevention—not just infectious disease. The extended five-year follow-up demonstrates that personalized neoantigen therapies can provide sustained benefits, moving this technology closer to becoming standard care for cancer patients at high risk of recurrence. As additional data from other tumor types accumulates, personalized cancer vaccines could reshape how oncologists approach preventing cancer’s return
